23 research outputs found
MK2 and ETV1 Are Prognostic Factors in Esophageal Adenocarcinomas
Background. Esophageal cancer is ranked in the top ten of diagnosed tumors worldwide. Even though
improvements in survival could be noticed over the last years, prognosis remains poor. ETS
translocation variant 1 (ETV1) is a member of a family of transcription factors and is phosphorylated
by mitogen-activated protein kinase (MAPK)-activated protein kinase 2 (MK2). Aim of this study was
to evaluate the prognostic role of MK2 and ETV1 in esophageal cancer.
Methods. Consecutive patients that underwent surgical resection at the department of surgery at the
Medical University of Vienna between 1991 and 2012 were included into this study. After
microscopic analysis, tissue micro arrays (TMAs) were created and immunohistochemistry was
performed with antibodies against MK2 and ETV1.
Results. 323 patients were included in this study. Clinical data was achieved from a prospective
patient data base. Nuclear overexpression of MK2 was observed in 143 (44.3%) cases for nuclear
staining and in 142 (44.0%) cases a cytoplasmic overexpression of MK2 was observed. Nuclear and
cytoplasmic ETV1 overexpression was detected in 20 cases (6.2%) and 30 cases (9.3%), respectively.
In univariate survival analysis, cMK2 and nETV1 were found to be significantly associated with
patients' overall survival. Whereas overexpression of cMK2 was associated with shorter, nETV1
was associated with longer overall survival. In multivariate survival analysis, both cMK2 and nETV1
were found to be independent prognostic factors for the subgroup of EAC as well.
Discussion. Expression of MK2 and ETV1 are prognostic factors in patients, with esophageal
adenocarcinoma
BigStitcher: reconstructing high-resolution image datasets of cleared and expanded samples.
Light-sheet imaging of cleared and expanded samples creates terabyte-sized datasets that consist of many unaligned three-dimensional image tiles, which must be reconstructed before analysis. We developed the BigStitcher software to address this challenge. BigStitcher enables interactive visualization, fast and precise alignment, spatially resolved quality estimation, real-time fusion and deconvolution of dual-illumination, multitile, multiview datasets. The software also compensates for optical effects, thereby improving accuracy and enabling subsequent biological analysis
Making the invisible visible: observing the UV-reversal effect in quartz using radiofluorescence
Audencel Immunotherapy Based on Dendritic Cells Has No Effect on Overall and Progression-Free Survival in Newly Diagnosed Glioblastoma: A Phase II Randomized Trial
Dendritic cells (DCs) are antigen-presenting cells that are capable of priming anti-tumor immune responses, thus serving as attractive tools to generate tumor vaccines. In this multicentric randomized open-label phase II study, we investigated the efficacy of vaccination with tumor lysate-charged autologous DCs (Audencel) in newly diagnosed glioblastoma multiforme (GBM). Patients aged 18 to 70 years with histologically proven primary GBM and resection of at least 70% were randomized 1:1 to standard of care (SOC) or SOC plus vaccination (weekly intranodal application in weeks seven to 10, followed by monthly intervals). The primary endpoint was progression-free survival at 12 months. Secondary endpoints were overall survival, safety, and toxicity. Seventy-six adult patients were analyzed in this study. Vaccinations were given for seven (3–20) months on average. No severe toxicity was attributable to vaccination. Seven patients showed flu-like symptoms, and six patients developed local skin reactions. Progression-free survival at 12 months did not differ significantly between the control and vaccine groups (28.4% versus 24.5%, p = 0.9975). Median overall survival was similar with 18.3 months (vaccine: 564 days, 95% CI: 436–671 versus control: 568 days, 95% CI: 349–680; p = 0.89, harzard ratio (HR) 0.99). Hence, in this trial, the clinical outcomes of patients with primary GBM could not be improved by the addition of Audencel to SOC